Picture of Arcturus Therapeutics Holdings logo

ARCT Arcturus Therapeutics Holdings Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Momentum

Relative Strength (%)
1m+4.2%
3m-19.06%
6m-6.32%
1yr-8.42%
Volume Change (%)
10d/3m+41.51%
Price vs... (%)
52w High-31.11%
50d MA+0.21%
200d MA+3.86%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-40.66%
Return on Equity-36.17%
Operating Margin-99.07%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Arcturus Therapeutics Holdings EPS forecast chart

Profile Summary

Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

Directors

Last Annual
December 31st, 2023
Last Interim
March 31st, 2024
Incorporated
January 28th, 2019
Public Since
May 22nd, 2013
No. of Shareholders
10
No. of Employees
180
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
26,931,826

ARCT Share Price Performance

Upcoming Events for ARCT

Q2 2024 Arcturus Therapeutics Holdings Inc Earnings Release

Q3 2024 Arcturus Therapeutics Holdings Inc Earnings Release

Similar to ARCT

Picture of 89bio logo

89bio

us flag iconNASDAQ Global Market

Picture of Abivax SA logo

Abivax SA

us flag iconNASDAQ Global Market

Picture of AC Immune SA logo

AC Immune SA

us flag iconNASDAQ Global Market

Picture of Acrivon Therapeutics logo

Acrivon Therapeutics

us flag iconNASDAQ Global Market

Picture of Adagene logo

Adagene

us flag iconNASDAQ Global Market

FAQ